Analysts Weigh Gilead’s Future In HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite recent sell-off on R&D cost worries, competitors’ patent expiry and safety issues could help.
You may also be interested in...
FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.
FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.
Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance
Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.